Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

ose in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended October 31, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Jennifer Anderson

(800) 987-8256 (212) 918-4642


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 21, 2014 (PRWEB) July 23, 2014 ... at Rutgers University. , The goal of ... across the full spectrum of scientists working in ... and development topics that represent the most promising ... programmed to:,     Provide faculty and ...
(Date:7/22/2014)... WASHINGTON D.C., June 22, 2014 Even within a phylum ... fly is distinguished among other arthropods for its cruelty -- ... and Central America, the fly is a most predatory sort ... male cricket, deposits a smear of larvae, and leaves its ... inside out. , None of this would be possible ...
(Date:7/22/2014)... Vibrate a solution of rod-shaped metal nanoparticles in water ... like tiny drill bits. Why? No one yet knows ... and Technology (NIST) have clocked their speedand it,s fast. ... rotate 10 times faster than any nanoscale object submerged ... dizzying rate has opened up the possibility that they ...
(Date:7/22/2014)... , July 22, 2014   BioTE ... therapy using natural, bio-identical hormone pellets, today announced ... MD to the company.   Dr. Rouzier is joining ... physician.      Dr. Rouzier was residency ... UCLA and is a board certified emergency physician ...
Breaking Biology Technology:The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3
... work showing how nanowires carved in impurity-laden diamond ... developed a scalable manufacturing process to craft arrays ... photon control. The development supports efforts to ... stage for diamond-based microchips. Additionally, the technology ...
... 2011 Applied Precision is proud to announce ... super-resolution microscopy system at McGill University in Montreal, ... is a super-resolution microscope utilizing proven three-dimensional structured ... in volume resolution and outstanding widefield imaging capabilities. ...
... Ohio, Oct. 18, 2011 Minimally Invasive Devices, Inc ... new product, FloShield PLUS , utilizing the novel Flo-X ... of the end of the laparoscope without removal from the ... MID,s FloShield laparoscopic visualization system. In the first 19 FloShield ...
Cached Biology Technology:Diamonds, silver and the quest for single photons 2Diamonds, silver and the quest for single photons 3Applied Precision Announces the 25th Installation of Its DeltaVision OMX Super-Resolution Microscope at McGill University 2
(Date:7/23/2014)... Tracking of blue whales by satellite over a 15-year ... whales consistently return to feed in specific locations each ... in the open-access journal PLOS ONE by ... data may be used to mitigate human threats to ... has been slow to recover since the establishment of ...
(Date:7/23/2014)... cystic fibrosis patients, scientists at the UNC School of ... that a new CF drug counteracts the intended beneficial ... published today in the journal Science Translational Medicine ... and loses its ability to function properly when in ... several insights into how novel CF pharmacotherapies could be ...
(Date:7/23/2014)... , , , , , ... , , , , ... diseases and extend healthy lifespan. The idea, they argue, would be to target the... , , ... , , , , , ... , , , , , , , Medicine ...
Breaking Biology News(10 mins):Blue whales' dangerous feeding grounds 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5
... several proteins in mice that might act as biomarkers ... step to finding a more reliable way to detect ... teenagers use illegally to boost muscle and reduce fat. ... San Francisco today, scientists John Kopchick and Juan Ding ...
... the White House must be enhanced so that the ... nationfrom energy and the environment, to national security, and ... collaborate internationally. The report,s primary recommendations are that: ... respected leader to be Assistant for Science and Technology ...
... 2008 Mary Tyler Moore, the Juvenile Diabetes Research ... M.D., presented the sixth annual "Excellence in Clinical Research ... annual conference today in Washington, DC. The recipients ... director of the JDRF Gene Therapy Center for Diabetes ...
Cached Biology News:Scientists find potential protein biomarkers for growth hormone 2White House science office needs upgrade 2White House science office needs upgrade 3Florida researchers receive JDRF 'Excellence in Clinical Research Award' 2